In addition, a clinical phase I/II trial with SR14716A (rimonabant), a CNR1 antagonist agonist showed that it produced serious adverse neuropsychiatric events such as anxiety, depression, and even suicidal ideation [45,46]. Here, CNR1 is linked to depressive symptom measurement.